Toward a cure for HIV-Seeking effective therapeutic vaccine strategies

European Journal of Immunology

Volumn 45, Issue 12, 2015, Pages 3215-3221

  Autran, Brigitte ^a,b  

^a INSERM   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

HIV; HIV neutralizing antibodies; Immune correlates of protection; T cell immunity to HIV; Therapeutic vaccines; Vector based vaccines

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; IMMUNOGENICITY; NONHUMAN; POXVIRIDAE; PRIORITY JOURNAL; REMISSION; VACCINATION; HIV INFECTIONS; HUMAN; IMMUNIZATION; IMMUNOLOGY; T LYMPHOCYTE;

AIDS VACCINES; HIV INFECTIONS; HUMANS; IMMUNIZATION; T-LYMPHOCYTES;

EID: 84951743744     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201545513     Document Type: Article

References (62)

1. International AIDS Society Scientific Working Group on HIV Cure, Deeks, S. G., Autran, B., Berkhout, B., Benkirane, M., Cairns, S. et al., Towards an HIV cure: a global scientific strategy. Nat. Rev. Immunol. 2012. 12: 607-614.
2. Katlama, C., Deeks, S. G., Autran, B., Martinez-Picado, J., van Lunzen, J., Rouzioux, C. et al., Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013, doi: pii: S0140-6736(13)60104-X. 10.1016/S0140-6736(13)60104-X.
3. Autran, B., Debre, P., Walker, B. and Katlama, C., Therapeutic vaccines against HIV need international partnerships. Nat. Rev. Immunol. 2003. 3: 503-508.
4. Autran, B., Carcelain, G., Combadiere, B. and Debre, P., Therapeutic vaccines for chronic infections. Science 2004. 305: 205-208.
5. Carcelain, G. and Autran, B., Immune interventions in HIV infection. Immunol. Rev. 2013. 254: 355-371.
6. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr, W. M., Lundgren, J., Neaton, J. D., Gordin, F., Abrams, D. et al., CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 2006. 355: 2283-2296.
7. Hütter, G., Nowak, D., Mossner, M., Ganepola, S., Müssig, A., Allers, K. et al., Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 2009. 360: 692-698.
8. Richman, D. D., Margolis, D. M., Delaney, M., Greene, W. C., Hazuda, D. and Pomerantz, R. J., The challenge of finding a cure for HIV infection. Science 2009. 323: 1304-1307.
9. Trono, D., Van Lint, C., Rouzioux, C., Verdin, E., Barré-Sinoussi, F., Chun, T. W. et al., HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010. 329: 174-180.
10. Hocqueloux, L., Prazuck, T., Avettand-Fenoel, V., Lafeuillade, A., Cardon, B., Viard, J. P. et al., Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010. 24: 1598-1601.
11. Saez-Cirion, A., Bacchus, C., Hocqueloux, L., Avettand-Fenoel, V., Girault, I., Lecuroux, C. et al., Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog. 2013. 9: e1003211.
12. Autran, B., Carcelain, G., Li, T. S., Blanc, C., Mathez, D., Tubiana, R. et al., Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997. 277: 112-116.
13. Dalod, M., Harzic, M., Pellegrin, I., Dumon, B., Hoen, B., Sereni, D., Deschemin, J. C. et al., Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. J. Infect. Dis. 1998. 178: 61-69.
14. Rosenberg, E. S., Billingsley, J. M., Caliendo, A. M. et al., Vigorous HIV-1 specific CD4+ T cell responses associated with control of viremia. Science 1997. 278: 1447-1450.
15. Guihot, A., Bourgarit, A., Carcelain, G. and Autran, B., Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus. Trends Immunol. 2011. 32: 131-137.
16. Oxenius, A., Price, D. A., Easterbrook, P. J. et al., Early highly active antiretroviral therapy for acute HIV infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc. Natl. Acad. Sci. USA 2000. 97: 3382-3387.
17. Ortiz, G. M., Wellons, M., Brancato, J., Vo, H. T., Zinn, R. L., Clarkson, D. E. et al., Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc. Natl. Acad. Sci. USA 2001. 98: 13288-13293.
18. Carcelain, G., Tubiana, R., Samri, A., Calvez, V., Delaugerre, C., Agut, H. et al., Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J. Virol. 2001. 75: 234-241.
19. Kinloch-de Loes, S. and Autran, B., HIV-1 therapeutic vaccines. J. Infect. Dis. 2002. 44: 152-159.
20. Pantaleo, G. and Koup, R. A., Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat. Med. 2004. 10: 806-810.
21. Kiepiela, P., Ngumbela, K., Thobakgale, C., Ramduth, D., Honeyborne, I., Moodley, E. et al., CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 2007. 13: 46-53.
22. Appay, V., Dunbar, P. R., Callan, M., Klenerman, P., Gillespie, G. M., Papagno, L. et al., Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 2002. 8: 379-385.
23. Migueles, S. A., Laborico, A. C., Shupert, W. L., Sabbaghian, M. S., Rabin, R., Hallahan, C. W. et al., HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 2002. 3: 1061-1068.
24. Martinez, V., Costagliola, D., Bonduelle, O., N'go, N., Schnuriger, A., Théodorou, I. et al., Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J. Infect. Dis. 2005. 191: 2053-2063.
25. Xie, J., Lu, W., Samri, A., Costagliola, D., Schnuriger, A., da Silva, B. C. M. et al., Distinct differentiation profile between HIV-Gag and Nef specific CD8+ T cells with preservation of CD27+ central memory T cells is dictated by HLA-B57/5801 and associated with virus control. AIDS 2010. 24: 2323-2329.
26. Almeida, J. R., Price, D. A., Papagno, L., Arkoub, Z. A., Sauce, D., Bornstein, E. et al., Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 2007. 204: 2473-2485.
27. Trkola, A., Kuster, H., Rusert, P., Joos, B., Fischer, M., Leemann, C. et al., Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 2005. 11: 615-622.
28. Autran, B., Costagliola, D., Murphy, R. and Katlama, C., Evaluating therapeutic vaccines in patients infected with HIV. Expert Rev. Vaccines 2004. 3(Suppl 1): S169-S177.
29. Mc Michael, A. J. and Hanke, T., HIV vaccines 1983-2003. Nat. Med. 2003. 9: 874-880.
30. Markowitz, M., Jin, X., Hurley, A., Simon, V., Ramratnam, B., Louie, M. et al., Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J. Infect. Dis. 2002. 186: 634-643.
31. Kinloch-de Loes, S., Hoen, B., Smith, D. E., Autran, B., Lampe, F. C., Philips, A. N. et al., Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J. Infect. Dis. 2005. 192: 607-617.
32. Goujard, C., Marcellin, F., Hendel-Chavez, H., Burgard, M., Meiffrédy, V., Venet, A. et al., Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 randomized study. AIDS Res. Hum. Retroviruses 2007. 23: 1105-1113.
33. Tubiana, R., Carcelain, G., Vray, M., Gourlain, K., Dalban, C., Chermak, A. et al., Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: the Vacciter study (ANRS 094). Vaccine 2005. 23: 4292-4301.
34. Lévy, Y., Gahéry-Ségard, H., Durier, C., Lascaux, A. S., Goujard, C., Meiffrédy, V. et al., Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 2005. 19: 279-286.
35. Kilby, J. M., Wang, R., Midvan, D. et al., A phase II randomized, partially blinded trial of antiretroviral therapy (ART), HIV-specific immunization and IL-2 cycles to promote efficient control of viral replication (ACTG A5024). J. Infect. Dis. 2006. 194: 1672-1676.
36. Autran, B., Murphy, R., Costagliola, D., Tubiana, R., Clotet, B., Gatell, J. et al., Greater viral rebound & reduced time to resume antretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 2008. 22: 1313-1322.
37. Papagno, L., Alter, G., Assoumou, L., Murphy, R. L., Garcia, F., Clotet, B. et al., Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. AIDS 2011. 25: 27-36.
38. Harrer, E., Bäuerle, M., Ferstl, B., Chaplin, P., Petzold, B., Mateo, L. et al., Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir. Ther. 2005. 10: 285-300.
39. Dorrell, L., Yang, H., Ondondo, B., Dong, T., di Gleria, K., Suttill, A. et al., Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J. Virol. 2006. 80: 4705-4716.
40. Harari, A., Rozot, V., Cavassini, M., Enders, F. B., Vigano, S., Tapia, G., Castro, E. et al., NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients. Eur. J. Immunol. 2012. 42: 3038-3048.
41. Schooley, R. T., Spritzler, J., Wang, H., Lederman, M. M., Havlir, D., Kuritzkes, D. R. et al., AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J. Infect. Dis. 2010. 202: 705-716.
42. Casazza, J. P., Bowman, K. A., Adzaku, S., Smith, E. C., Enama, M. E., Bailer, R. T. et al., Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J. Infect. Dis. 2013. 11.
43. Achenbach, C. J., Assoumou, L., Deeks, S. L. et al. Therapeutic intensification followed by HIV DNA prime and rAd 5-boost vaccination increases HIV-specific immunity but does not affect the reservoir: a multicentre randomised clinical trial (EraMune 02). Lancet HIV 2015. 2: e82-e91.
44. Hammer, S. M., Sobieszczyk, M. E. et al., Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 2013. 369: 2083-2092.
45. García, F., Lejeune, M., Climent, N., Gil, C., Alcami, J., Morente, V. et al., Therapeutic immunization with dendritic cells loaded with inactivated autologous HIV-1 in chronic HIV-1 infected patients. J. Infect. Dis. 2005. 195: 1680-1685.
46. Garcia, F., Climent, N., Assoumou, L., Gil, C., Gonzalez, N., Alcami, J. et al., A therapeutic dendritic cell-based vaccine for HIV-1 infection. J. Infect. Dis. 2011. 203: 473-478.
47. Gandhi, R. T., O'Neill, D., Bosch, R. J., Chan, E. S., Bucy, R. P., Shopis, J. et al., A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 2009. 27: 6088-6094.
48. Routy, J. P., Boulassel, M. R., Yassine-Diab, B., Nicolette, C., Healey, D., Jain, R. et al., Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin. Immunol. 2010. 134: 140-147.
49. Combadière, B., Vogt, A., Mahé, B., Costagliola, D., Hadam, S., Bonduelle, O. et al., Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial. PLoS One 2010. 5: e10818.
50. Lisziewicz, J., Bakare, N., Calarota, S. A., Bánhegyi, D., Szlávik, J., Ujhelyi, E. et al., Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals. PLoS One 2012. 7: e35416.
51. Adam, L., Le Grand, R. and Martinon, F., Electroporation-mediated intradermal delivery of DNA vaccines in nonhuman primates. Methods Mol. Biol. 2014. 1121: 309-313.
52. Chomont, N., El-Far, M., Ancuta, P., Trautmann, L., Procopio, F. A., Yassine-Diab, B., Boucher, G. et al., HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 2009. 15: 893-900.
53. Descours, B., Avettand-Fenoel, V., Blanc, C., Samri, A., Mélard, A., Supervie, V. et al., ALT ANRS CO15 study group. Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. Clin. Infect. Dis. 2012. 54: 1495-1503.
54. Dalmasso, C., Carpentier, W., Meyer, L., Rouzioux, C., Goujard, C., Chaix, M. L. et al., Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS One 2008. 3: e3907.
55. Autran, B., Descours, B., Avettand-Fenoel, V. et al., Elite controllers as a model of functional cure. Curr. Opin. HIV AIDS 2011. 6: 181-187.
56. Shan, L., Deng, K., Shroff, N., Durand, C., Rabi, S., Yang, H. et al., Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012. 36: 491-501.
57. Delaugerre, C., Gourlain, K., Tubiana, R., Carcelain, G., Marcelin, A. G., Chouquet, C. et al., Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial). Antivir. Ther. 2003. 8: 233-237.
58. Persaud, D., Luzuriaga, K., Ziemniak, C., Muresan, P., Greenough, T., Fenton, T. et al., Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4R T-cell latent HIV reservoir. AIDS 2011. 25: 2227-2234.
59. Katlama, C., Lambert-Niclot, S., Assoumou, L., Papagno, L., Lecardonnel, L., Tambussi, G. et al., Impact of interleukin 7 and Raltegravir plus Maraviroc intensification on total HIV DNA reservoir: results from ERAMUNE 01. AIDS 2015, in press.
60. Shingai, M., Donau, O. K., Plishka, R. J., Buckler-White, A., Mascola, J. R., Nabel, G. J. et al., Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 2014. 211: 2061-2074.
61. Burton, D. R. and Mascola, J. R., Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 2015. 16: 571-576.
62. Caskey, M., Klein, F., Lorenzi, J. C. C. et al., Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 2015. 522: 487-491.